In the latest prospective, randomized controlled pilot study to date, 24 COVID-19 patients with refractory shock, hypercytokinemia (defined as IL-6 ≥500 ng/L), and indication for RRT or ECMO were enrolled. This evidence concerns the gene IL6 and COVID-19.